Navigation Links
FDA Approves Seasonal Influenza Vaccine Fluarix for Pediatric Use
Date:10/19/2009

SILVER SPRING, Md., Oct. 19 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved use of the seasonal influenza vaccine Fluarix for children ages 3 years to 17 years. Previously, this vaccine, which contains inactivated (killed) influenza A and B viruses, had been approved for use in adults, ages 18 years and older.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO)

The safety and effectiveness of Fluarix for use in children ages 3 years and older is documented by a U.S. study comparing 2,115 children who received Fluarix with 1,210 children who received Fluzone, a different influenza vaccine already licensed by the FDA for use in children ages 6 months and older. Study results showed that children 3 years and older vaccinated with Fluarix and Fluzone produced similar amounts of antibodies in the blood at levels considered likely to be protective against seasonal influenza.

Fluarix is a seasonal influenza vaccine not intended to protect against the 2009 H1N1 influenza virus.

"This approval of an additional seasonal influenza vaccine for children provides help in protecting them against influenza," said Karen Midthun, M.D., acting director of the FDA's Center for Biologics Evaluation and Research. "Children are very vulnerable to the influenza virus and are more likely to be hospitalized for associated problems."

With today's approval, there are now four companies approved by the FDA to manufacture seasonal influenza vaccine for use in children.

Influenza is far more dangerous than the common cold for children, who often require medical care, especially if they are younger than 5 years. It is best to vaccinate children each fall, but vaccination also can occur in the winter months when influenza season often peaks.

Common adverse events experienced after administration of Fluarix are typical of those for flu shots and include pain, redness, and swelling at the injection site as well as irritability, loss of appetite, and drowsiness.

Because Fluarix contains a small amount of egg protein, it should not be administered to anyone allergic to eggs or egg products.

Fluarix is manufactured by GlaxoSmithKline Biologicals of Dresden, Germany.

For more information:

FDA Web site on Influenza Virus Vaccine Safety and Availability

http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/VaccineSafety/ucm110288.htm

Media Inquiries: Peper Long, 301-796-4671, mary.long@fda.hhs.gov

Consumer Inquiries: 888-INFO-FDA

SOURCE U.S. Food and Drug Administration


'/>"/>
SOURCE U.S. Food and Drug Administration
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves New Treatment for Advanced Form of Kidney Cancer
2. FDA Approves Elitek(R) (rasburicase) for Management of Plasma Uric Acid Levels in Adults with Leukemia, Lymphoma, and Solid Tumors Receiving Anti-Cancer Therapy
3. FDA Approves Cervarix, GlaxoSmithKlines Cervical Cancer Vaccine
4. U.S. Food and Drug Administration Approves CRESTOR(R) for Use in Pediatric Patients With Heterozygous Familial Hypercholesterolemia
5. Chinese Food and Drug Administration Approves Gabexate Mesylate as Pharmaceutical Raw Material
6. FDA Approves New Indication For Mirena(R) to Treat Heavy Menstrual Bleeding in IUD Users
7. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
8. Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia
9. FDA Approves Tekturna HCT(R) as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent
10. FDA Approves ADCIRCA(TM) (Tadalafil) Tablets for the Treatment of Pulmonary Arterial Hypertension
11. FDA Approves Vanda Pharmaceuticals Fanapt(TM) for the Treatment of Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... , Jan. 17, 2017 Angel MedFlight Worldwide ... Capt. Mark Kelly as the keynote speaker ... Conference in Washington D.C. April ... speak on Friday morning, April 21 at the Gaylord ... across the country are expected to attend the annual ...
(Date:1/17/2017)... , Jan. 17, 2017  Market Research Future published a ... Devices Market is expected to reach USD 33.6 million during the ... Market Highlights ... The Global Endoscopy Devices Market has been examined as a swiftly ... there is huge demand for endoscopy device in various regions.  The ...
(Date:1/17/2017)... -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating ... ("Anthera" or the "Company") (NASDAQ: ANTH ). Such ... investigation by visiting the firm,s site: www.bgandg.com/anth .   ... officers and/or directors have violated Sections 10(b) and 20(a) of ... ...
Breaking Medicine Technology:
(Date:1/17/2017)... ... January 17, 2017 , ... Metro Development Group has ... high speed technology into the fabric of an entire community. A highlight of ... and wellness in a yet-to-be-named, health focused campus. Leading this initiative in partnership ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... ... Medical Center joined the Peoples Health network on Dec. 1, 2016. Peoples ... , “JenCare Senior Medical Center is an exciting addition to our provider network, ...
(Date:1/17/2017)... ... January 17, 2017 , ... Neil H. Greco Insurance Agency, a northern New ... the region, is launching a charity drive to raise awareness of heart disease and ... killer in America, and is responsible for 1 in every 4 deaths at the ...
(Date:1/17/2017)... ... January 17, 2017 , ... Seceon ... cyber threats in real-time, today announced a strategic partnership with TechLab Security, ... Joining other Seceon partners, TechLab Security has become a strategic partner and a ...
(Date:1/17/2017)... CA (PRWEB) , ... January 17, 2017 , ... Many people make New Year’s resolutions ... Robert Mondavi is making it easier for people who want to kick off ... both new and existing patients. , These special offers include: , ...
Breaking Medicine News(10 mins):